Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.

ibdwatch

Related Articles Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. Lancet Gastroenterol Hepatol. 2019 Jun 10;: Authors: Schreuders EH, Grobbee EJ, Nieuwenburg SAV, Kapidzic A, van Roon AHC, van Vuuren AJ, Lansdorp-Vogelaar I, Spijker WWJ, Izelaar K, Bruno MJ, Kuipers EJ, Spaander MCW Abstract BACKGROUND: Faecal immunochemical test (FIT)-based colorectal cancer screening requires successive rounds for maximum preventive effect. Advanced neoplasia can bleed intermittently and thus might be missed by single faecal sampling. Few studies have been done on two sample…

Read More

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.

ibdwatch

Related Articles Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2019 Jun 12;: Authors: Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M Abstract OBJECTIVES: To better understand the real-world impact of biologic therapy in persons with Crohn’s disease (CD) and UC, we evaluated the effect of marketplace introduction of infliximab on the population rates of hospitalisations and surgeries and public payer drug…

Read More

Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn’s disease perianal fistulas.

ibdwatch

Related Articles Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn’s disease perianal fistulas. J Crohns Colitis. 2019 Jun 14;: Authors: Barnhoorn MC, Wasser MNJM, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, van der Woude CJ, Roelen DL, Zwaginga JJ, Verspaget HW, Fibbe WE, Hommes DW, Peeters KCMJ, van der Meulen-de Jong AE Abstract BACKGROUND & AIMS: The long-term safety and efficacy of allogeneic bone marrow-derived mesenchymal stromal cell (bmMSC) therapy in perianal Crohn’s disease (CD) fistulas is unknown. We aimed to…

Read More

Decellularized Human Gut as a Natural 3D Platform for Research in Intestinal Fibrosis.

ibdwatch

Decellularized Human Gut as a Natural 3D Platform for Research in Intestinal Fibrosis. Inflamm Bowel Dis. 2019 Jun 14;: Authors: Giuffrida P, Curti M, Al-Akkad W, Biel C, Crowley C, Frenguelli L, Telese A, Hall A, Tamburrino D, Spoletini G, Fusai G, Tinozzi FP, Pietrabissa A, Corazza GR, De Coppi P, Pinzani M, Di Sabatino A, Rombouts K, Mazza G Abstract BACKGROUND: The current methodologies for the identification of therapeutic targets for inflammatory bowel disease (IBD) are limited to conventional 2-dimensional (2D) cell cultures and animal models. The use of…

Read More

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring.

ibdwatch

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring. Gastroenterology. 2019 Jun 10;: Authors: Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-Mark A, Rinawi F, Cohen S, Topf-Olivestone C, Shaoul R, Yerushalmi B, Shamir R Abstract BACKGROUND & AIMS: Proactive monitoring of drug trough concentrations and antibodies against drugs might help determine whether patients are likely to respond to treatment and increase efficacy. We investigated whether proactive drug monitoring is associated with higher rates…

Read More

Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis.

ibdwatch

Related Articles Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 Jun 11;: Authors: Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR Abstract BACKGROUND: Chronic antibiotic-refractory pouchitis (CARP) occurs in up to 15% of patients with ulcerative colitis (UC) following proctocolectomy with ileal pouch-anal anastomosis (IPAA). AIM: To investigate the effectiveness of ustekinumab in the treatment of CARP. METHODS: This was a retrospective single-center study of UC…

Read More

Mortality After First Hospital Admission for Inflammatory Bowel Disease: A Nationwide Registry Linkage Study.

ibdwatch

Mortality After First Hospital Admission for Inflammatory Bowel Disease: A Nationwide Registry Linkage Study. Inflamm Bowel Dis. 2019 Mar 27;: Authors: Opstelten JL, Vaartjes I, Bots ML, Oldenburg B Abstract BACKGROUND: The goal of this study was to determine long-term mortality and causes of death in patients after hospitalization for inflammatory bowel disease (IBD). METHODS: A cohort of patients admitted to the hospital because of IBD for the first time between 1998 and 2010 was identified by linkage of nationwide Dutch registries. Mortality risks and causes of death in Crohn’s…

Read More

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.

ibdwatch

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2019 Jun 10;: Authors: Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP Abstract BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn’s disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of…

Read More
<< Go Back